Clinical trial
An Open Label, Multicenter, Safety and Efficacy Phase II Study of PRL3-Zumab in Solid Tumors
NCT07541001 is registered in ClinicalTrials.gov with Intra-IMMUSG Pte Ltd as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open Label, Multicenter, Safety and Efficacy Phase II Study of PRL3-Zumab in Solid Tumors
- Lead sponsor
- Intra-IMMUSG Pte Ltd
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- August 30, 2021
- Completion date
- December 1, 2026
- Enrollment
- 60 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
advanced malignant solid tumor